A

AbbVie

Global biopharmaceutical company developing medicines

Technicien de maintenance CVC

Full-TimeUpdated on 10/23/2026
No salary listed
Mid, Senior
Martillac, France
In Person
Building TradesHVAC & Building Systems

About the job

Requirements
  • Training in industrial maintenance at BTS level or BTS in climate/energy engineering, or at least 3 years of experience maintaining heating, air-conditioning, or refrigeration installations.
  • Alternatively, a Bac professionnel qualification with 3 years of climate-engineering experience when completed through an apprenticeship, or 5 years of climate-engineering experience without an apprenticeship.
  • Knowledge of operating air-treatment units, direct-expansion air conditioning, boiler rooms, and chilled-water production equipment.
  • Knowledge of electrotechnics, including troubleshooting control panels.
  • Ability to apply troubleshooting and failure-analysis methods.
  • Knowledge of automation, including understanding Grafcet, as well as regulation and instrumentation.
  • Ability to communicate clearly and precisely, both orally and in writing, with different stakeholders.
  • Ability to work in a team, analyze and synthesize information, and handle several projects simultaneously.
  • Ability to identify problematic situations and proactively propose suitable solutions.
  • Basic English reading comprehension.
  • Good command of Excel, computerized maintenance management systems (CMMS), Word, and OneNote.
Responsibilities
  • Operate HVAC and associated utility installations, including chillers, air-treatment units, boiler rooms, and airflow-related equipment such as weighing booths, fume cupboards, and hoods.
  • Plan and perform preventive, corrective, and improvement maintenance in accordance with the manager’s instructions, annual maintenance plan, and Good Manufacturing Practice (GMP) requirements.
  • Monitor and follow up on work performed by HVAC contractors for technical expertise, projects, improvements, and maintenance operations.
  • Contribute to continuous improvement and propose improvements within the team.
  • Participate in inspection rounds for equipment within the assigned scope.
  • Document interventions in full according to GMP requirements, including in logbooks and the computerized maintenance management system (CMMS).
  • Propose and implement optimization actions for HVAC systems.
  • Manage parts and supplies needed for maintenance operations.
  • Participate with the manager in revising maintenance contracts.
  • Maintain the qualified and validated state of installations and update associated documentation.
  • Ensure regulatory compliance, including refrigerant management, gas-consumption monitoring, waste traceability, and leak testing.
  • Participate in studies and documentary validation for new HVAC equipment.
  • Contribute to writing specifications and requests for proposals to purchase or modify installations.
  • Participate in the acceptance, validation, and qualification phases for new HVAC equipment and systems.
  • Define maintenance schedules and integrate them into the computerized maintenance management system (CMMS).
  • Set up maintenance contracts for new equipment.
  • Participate with the methods team in failure mode and effects analysis (FMEA) to anticipate risks and failures.
  • Support technical training on new equipment and write work instructions.
  • Manage alarms and actions during on-call duty in accordance with the site on-call agreement.
  • Work day hours from 8:30 a.m. to 4:30 p.m.

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

4%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Oct 22nd, 2026
Abbott stock: $247,767 in shares yields $500 a month in dividends ahead of Q3 earnings

Abbott Laboratories will report third-quarter earnings before the market opens on Wednesday, October 21. Analysts expect earnings of $1.41 per share, up from $1.30 a year earlier, and revenue of $12.99 billion, against $11.37 billion last year. On October 16, TD Cowen analyst Joshua Jennings reiterated a Buy rating and a $135 price target. Abbott pays a quarterly dividend of 63 cents per share ($2.52 a year), a yield of 2.42%. To earn $500 a month ($6,000 a year) from dividends alone, an investor would need about 2,381 shares, or roughly $247,767.

Yahoo Finance
Oct 21st, 2026
Retirees swap Social Security for 5 dividend stocks yielding up to 6.64%

Retirees looking for income beyond Social Security are turning to dividend stocks. The 2027 cost-of-living adjustment is tracking toward 3.3%, and five companies from different industries were screened for dividend safety first, then yield. Verizon yields 6.64% and Altria 6.17%. Verizon's free cash flow guidance of $21.94 billion to $22.14 billion covers its roughly $11.76 billion annual dividend. Altria's payout is about 79% of the low end of its 2026 earnings guidance. Realty Income pays monthly at a 5.99% yield and has raised its dividend 115 consecutive quarters. Enbridge yields 5.95%. AbbVie yields 2.48%, but its quarterly dividend has grown from $0.40 in 2013 to $1.73 in 2026. Risks include satellite competition for Verizon, falling cigarette volumes for Altria, and currency swings for Enbridge.

Yahoo Finance
Oct 19th, 2026
Merck and AbbVie shares jump 39% and 24% in 2026 as dividend picks for a decade

Healthcare stocks are rebounding in 2026, led by Merck and AbbVie. Merck shares have climbed 39% and AbbVie's 24%, against about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating Wall Street estimates. Keytruda sales hit $8.4 billion, though the drug will likely lose patent exclusivity by 2028. A subcutaneous version, Keytruda Qlex, may help retain market share. Merck's forward dividend yield is 2.3%. AbbVie's revenue grew 10.2% to almost $17 billion, with adjusted earnings per share up 22.9% to $3.65. Skyrizi and Rinvoq sales each rose about 24%, and neither faces US competition until 2033 and 2037 respectively. AbbVie has raised its dividend for 54 straight years, including its time as part of Abbott Laboratories.

Yahoo Finance
Oct 19th, 2026
Buffett warns of a "gambling mood" in markets; Vertex, Eli Lilly and AbbVie built to weather a drop

Warren Buffett, now Berkshire Hathaway's chairman emeritus, gave his bluntest warning yet at the May shareholder meeting. "We've never had people in a more gambling mood than now," he told CNBC, pointing to individuals rushing into short-term options and betting on markets. He said this behaviour is risky for those taking part and may threaten the market, possibly leading to a drop. The article suggests drugmakers as defensive picks, since patients need treatments in any economy. Vertex Pharmaceuticals leads in cystic fibrosis treatment. Eli Lilly's tirzepatide drugs, Mounjaro and Zepbound, earned more than $14 billion of its $23 billion quarterly revenue. AbbVie's Rinvoq and Skyrizi each grew 24%, and it has raised its dividend for more than 50 consecutive years.

Yahoo Finance
Oct 18th, 2026
Ken Griffin's Citadel boosts AbbVie stake 546% in Q2 as defensive dividend play

Citadel founder and chief executive officer Ken Griffin made healthcare his biggest bet in the second quarter. He bought 2.7 million AbbVie shares, a 546% increase from the previous quarter, and added 6.7 million shares of Abbott Laboratories, up 349%. He also raised his Eli Lilly stake by 291%, the third-biggest individual equity add. The moves suggest a defensive stance. Healthcare stocks tend to hold up in downturns, and both AbbVie and Abbott are Dividend Kings, having raised dividends for 54 straight years. AbbVie yields 2.65% and trades at 16 times forward earnings. In the second quarter, its adjusted earnings rose 23% and net revenue rose 10%. Some 75% of analysts covering the stock rate it a buy.